An open-label Phase II study of combination of TSR-042, bevacizumab, and niraparib in patients with platinum-resistant ovarian cancer (OC): Cohort A of the OPAL trial

被引：0
作者：
Liu, Joyce [1 ]
Gunderson, Camille [2 ]
Hendrickson, Andrea Wahner [3 ]
Ratner, Elena [4 ]
Diver, Elisabeth [5 ]
Moroney, John [6 ]
Arend, Rebecca C. [7 ]
Louie-Gao, Melinda [8 ]
Wang, Sarah [8 ]
Luptakova, Katarina [8 ]
Konecny, Gottfried E. [9 ]
机构：
[1] Dana Farber Canc Inst, Boston, MA 02115 USA
[2] Univ Oklahoma, Hlth Sci Ctr, Stephenson Canc Ctr, Oklahoma City, OK USA
[3] Mayo Clin, Dept Oncol, Rochester, MN USA
[4] Yale Univ, Sch Med, Dept Obstet Gynecol & Reprod Sci, New Haven, CT USA
[5] Stanford Univ, Sch Med, Dept Obstet & Gynecol, Stanford, CA 94305 USA
[6] Univ Chicago Med, Dept Obstet & Gynecol, Chicago, IL USA
[7] Univ Alabama Birmingham, Obstet & Gynecol, Birmingham, AL USA
[8] TESARO Inc, Waltham, MA USA
[9] Univ Calif Los Angeles, Med Ctr, Dept Med, Santa Monica, CA USA
来源：
CANCER RESEARCH | 2019年 / 79卷 / 13期
关键词：
D O I：
10.1158/1538-7445.AM2019-CT157
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
CT157
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Phase II study of sodium valproate in combination with oral etoposide in platinum-resistant ovarian cancer
    Thejeswar, N.
    Goenka, L.
    Dubashi, B.
    Kayal, S.
    Jayanthi, M.
    Barathi, D.
    Ganesan, P.
    ANNALS OF ONCOLOGY, 2022, 33 : S1510 - S1510
  • [42] OVARIO: A single-arm, open-label phase II study of maintenance therapy with niraparib plus bevacizumab (bev) in patients (pts) with advanced ovarian cancer (OC) after response to frontline platinum-based chemotherapy (chemo)
    Hardesty, M.
    Hope, J. M.
    Krivak, T.
    Chen, J.
    Wainszelbaum, M.
    Gupta, D.
    Richardson, D.
    ANNALS OF ONCOLOGY, 2018, 29
  • [43] Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial
    Pfisterer, Jacobus
    Shannon, Catherine M.
    Baumann, Klaus
    Rau, Joern
    Harter, Philipp
    Joly, Florence
    Sehouli, Jalid
    Canzler, Ulrich
    Schmalfeldt, Barbara
    Dean, Andrew P.
    Hein, Alexander
    Zeimet, Alain G.
    Hanker, Lars C.
    Petit, Thierry
    Marme, Frederik
    El-Balat, Ahmed
    Glasspool, Rosalind
    de Gregorio, Nikolaus
    Mahner, Sven
    Meniawy, Tarek M.
    Park-Simon, Tjoung-Won
    Mouret-Reynier, Marie-Ange
    Costan, Cristina
    Meier, Werner
    Reinthaller, Alexander
    Goh, Jeffrey C.
    L'Haridon, Tifenn
    Hay, Sally Baron
    Kommoss, Stefan
    du Bois, Andreas
    Kurtz, Jean-Emmanuel
    LANCET ONCOLOGY, 2020, 21 (05) : 699 - 709
  • [44] Topacio: Preliminary activity and safety in patients (pts) with platinum-resistant ovarian cancer (PROC) in a phase 1/2 study of niraparib in combination with pembrolizumab
    Konstantinopoulos, P. A.
    Munster, P.
    Forero-Torez, A.
    Holloway, R. W.
    Schwartzberg, L.
    Matulonis, U. A.
    Wang, J.
    Guo, W.
    Dezube, B.
    Vinayak, S.
    GYNECOLOGIC ONCOLOGY, 2018, 149 : 246 - 246
  • [45] A phase II, open-label study of ispinesib (SB-715992) in patients with platinum/taxane refractory or resistant relapsed ovarian cancer
    Shahin, M. S.
    Braly, P.
    Rose, P.
    Malpass, T.
    Bailey, H.
    Alvarez, R. D.
    Hodge, J.
    Bowen, C.
    Buller, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)
  • [46] Efficacy and Safety of Low-Dose Lenvatinib and Toripalimab in Patients With Recurrent Platinum-Resistant Ovarian Cancer: Study Protocol of a Multicenter, Open-Label, Single-Arm, Phase II Clinical Trial
    Su, Hao
    Shang, Xiao
    Liu, Hongruo
    Wang, Yutong
    Yu, Yang
    Xu, Yanhua
    Jiang, Kui
    Feng, Fengzhi
    INTERNATIONAL JOURNAL OF WOMENS HEALTH, 2025, 17 : 325 - 333
  • [47] Combination of Bevacizumab and Chemotherapy for Platinum-Resistant Recurrent Ovarian Cancer: Some Observations About the AURELIA Trial
    Tomao, Federica
    Tomao, Silverio
    Panici, Pierluigi Benedetti
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (31) : 3580 - 3580
  • [48] Phase II study of bevacizumab in patients with platinum-resistant ovarian cancer or peritoneal serous cancer (vol 25, pg 5180, 2007)
    Cannistra
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (10) : 1773 - 1773
  • [49] Bevacizumab, eribulin, and oxaliplatin in patients with platinum-resistant ovarian carcinomas: A phase II study with biomarker analysis.
    Takano, Masashi
    Kouta, Hiroko
    Kudoh, Kazuya
    Kita, Tsunekazu
    Yoshikawa, Tomoyuki
    Kikuchi, Ryoko
    Matsuura, Hiroko
    Miyamoto, Morikazu
    Goto, Tomoko
    Furuya, Kenichi
    Kikuchi, Yoshihiro
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.
    Moore, Kathleen N.
    Chambers, Setsuko K.
    Hamilton, Erika Paige
    Chen, Lee-May
    Oza, Amit M.
    Ghamande, Sharad A.
    Konecny, Gottfried E.
    Plaxe, Steven C.
    Spitz, Daniel Lewis
    Geenen, Jill J. J.
    Troso-Sandoval, Tiffany A.
    Cragun, Janiel M.
    Imedio, Esteban Rodrigo
    Kumar, Sanjeev
    Mugundu, Ganesh M.
    Lai, Zhongwu
    Chmielecki, Juliann
    Jones, Suzanne Fields
    Spigel, David R.
    Cadoo, Karen Anne
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345